DualityBio tries to float again
The group expects to raise nearly $170m.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Hello BridgeBio, farewell Syros and Achilles
One step forward, two steps back for biotech.
